Hypochlorous acid as an antiseptic in the care of patients with suspected COVID-19 infection

See "Ácido hipocloroso como antiséptico en la atención al paciente con sospecha de infección por COVID-19" in Arch Soc Esp Oftalmol, volume 97 on page 77.

Go to:

Abstract

Purpose

The SARS-CoV-2 virus, which causes COVID-19 disease, is transmitted by aerosols or by contact with infected surfaces. The route of entry to the body is through the nasal, oral or conjunctival mucosa. Health workers must use effective protection measures against the entry of the virus into mucous membranes, both physical and antiseptic filters. There is an antiseptic used in Ophthalmology that we believe could have virucidal action against the SARS-CoV-2 virus, formulated based on 0.01% hypochlorous acid.

Methods

An exhaustive search has been carried out in the databases of Pubmed and Web of Science to identify relevant articles on the virucidal activity of hypochlorous acid in different concentrations until October 4, 2020.

Results

There is evidence of the virucidal efficacy of 0.01% hypochlorous acid against SARS-CoV-2. According to the different scientific publications reviewed, hypochlorous acid has virucidal efficacy against different viruses, among them, SARS-CoV-2.

Conclusions

The 0.01% hypochlorous acid could act as an effective antiseptic against SARS-CoV-2, exerting a barrier on the mucosa to prevent COVID-19 infection. It can be used on the eyes, nose and mouth. We consider it necessary to assess its use in the protocol for patient health care in ophthalmology consultations, as well as to recommend its use to the general population to reduce viral load and/or prevent transmission of infection. Additional in vivo studies would be required to confirm its antiseptic action.

Keywords: Hypochlorous acid, Antiseptic, SARS-CoV-2, COVID-19, Conjunctivitis, Virucidal

Go to:

Introduction

The rapid spread and infectiousness of the SARS-CoV-2 virus forces us to be constantly on the lookout for protective measures. Transmission occurs by aerosols or by contact with infected surfaces1. The pathway of entry into the body is through the nasal, oral or conjunctival2 mucosa. One of the routes of transmission of SARS-CoV-2 is through tears and can produce conjunctivitis3, 4 as a symptom. In vitro and in vivo studies have shown that the eye may serve a dual purpose for the establishment of infection. On the one hand, it would serve as a gateway and on the other hand, as a site of virus replication as has been seen to occur with respiratory viruses5.

In 2020, The Lancet published the first systematic review and meta-analysis addressing the issue of ocular manifestations or complications due to SARS-CoV-2 infection and positivity by reverse transcription polymerase chain reaction (RT-PCR) of tear or conjunctival secretion samples6. The meta-analysis showed that in patients with COVID-19, 3.17% had ocular manifestation, but only 1.94% of them had positive RT-PCR of conjunctival smear. However, despite the presence of virus in the ocular fluid, only 33.3% of patients showed signs of conjunctivitis/conjunctival chemosis or red eyes. On the other hand, among patients with COVID-19-associated conjunctivitis/red eyes, only 28.65% showed evidence of the presence of the virus in the ocular fluid. That is, the absence of ocular symptoms does not mean that the virus is not present in the ocular fluid or that the appearance of ocular symptoms is related to the presence of the virus6.

There are other international studies not included in the previous review, such as that of Xia et al.7, in which they prospectively analyzed the presence of SARS-CoV-2 in tears and conjunctival secretion of patients with COVID-19. In their analysis, they only isolated the virus in the tear of one patient with conjunctivitis. Patients without ocular symptoms had a negative RT-PCR. However, they indicated that the low abundance of virus in tear and conjunctival secretions does not eliminate the risk of transmission through conjunctival tissue.

In the light of these data, healthcare workers are advised to take appropriate precautions regardless of the presence or absence of ocular manifestations, as lack of eye protection has been associated with an increased risk of SARS-CoV-2 transmission8. Therefore, the American Academy of Ophthalmology recommends ophthalmologists to take special care with patients given the proximity of the patient's nose and mouth during ophthalmic examination and the risk of exposure to tears that may potentially contain virus9.

Currently, for the adequate protection of healthcare personnel, only physical filters such as goggles and masks are used. However, in addition to these physical barriers, antiseptic substances capable of eliminating the virus at the point of entry such as the conjunctival, oral and nasal mucosa should be sought in order to increase protection against SARS-CoV-2. An antiseptic substance is capable of destroying or inhibiting the reproduction of microorganisms on living tissue. A disinfectant performs the same function, but on an inanimate surface11.

One of the disinfectants approved for the elimination of SARS-CoV-2 is hypochlorous acid12. Hypochlorous acid results from the union of acid chlorine oxide (Cl–) with water (H2O). Chemically it can be described as an undissociated oxygen-dependent, unstable and reactive chlorine ion. The effectiveness of hypochlorous acid lies in its highly oxidizing capacity. It is a reactive oxygen species, and is produced by macrophages and neutrophils, in what is known as a "respiratory burst" during the fight against pathogens13. It has a broad spectrum, fast action and a wide margin of safety, so it is used to keep in check and prevent a large number of skin and mucosal infections14. Hypochlorous acid 0.01% has been approved by the Australian Medicines Agency, the Australian Register of Therapeutics Goods (ARTG) as an effective disinfectant against COVID-1915.

The aim of this study was to review the scientific evidence on the virucidal activity of hypochlorous acid against SARS-CoV-2. As the entry point of SARS-CoV-2 virus is through the mucous membranes, the present study is relevant because it is an antiseptic substance for use in the nasal, oral and conjunctival mucous membranes.

Go to:

Methods

Scientific literature search strategy

The main resources used for the medical literature search were the PubMed and Web of Science databases. An exhaustive search of studies published in English or with an abstract in English up to 1 October 2020 was conducted to identify relevant information on the virucidal activity of hypochlorous acid at different concentrations. The keywords used were: hypochlorous acid, antiseptic, SARS-CoV-2, COVID-19, conjunctivitis and virucidal which were used independently and in different combinations. Reference lists of the analysed articles were also considered as a potential source of information.

Go to:

Results

The literature search produced a total of 20 articles, from which the following information was extracted.

Studies on the virucidal activity of hypochlorous acid

There is published data from the 1960s, where Speir reported possible antiviral activity of chloride or halide salt compounds16.

A study carried out by the Animal Health Research Centre (IRTA-CReSA), in cell models, showed that hypochlorous acid is able to inhibit the replication of SARS-CoV-2 after 30 s, with a higher virucidal capacity after 10 min.

Kim et al. tested the efficacy of hypochlorous acid at low doses on nasal mucosa, with antibacterial, antifungal and antiviral activity. They observed more than 99% bactericidal or fungicidal activity for all species except Candida albicans in tap water at pH 7.0 and 8.4. In addition, it achieved a 3.2 log10 reduction in cells exposed to human influenza A virus17.

In the study by Ramalingman et al. different cells were infected with DNA and RNA viruses. These included a human coronavirus, HCoV-229E, in liver cells. They found that viral inhibition by hypochlorous acid was an intracellular process and not a direct effect of chloride on viral particles or viral uptake and that this process did not occur by cytotoxicity18.

Landa-Solis et al. observed complete inactivation of HIV-1 and reduction of 3-log10 in adenovirus after 5 min of contact and complete inactivation when contact occurred for 10 min against 20 ppm hypochlorous acid (0.002%)19.

Taharaguchi et al. studied the effect of hypochlorous acid 60 ppm (0.006%) on mouse hepatitis virus, Sendai virus, lymphocytic choriomeningitis virus, Bordetella bronchiseptica, Pasteurella pneumotropica, Corynebacterium kutscheri, Staphylococcus aureus and Pseudomonas aeruginosa. At 5 min, the determination of virus was practically null20.

Go to:

Discussion

Hypochlorous acid can act as an effective antiseptic against different viruses, according to the different in vitro studies carried out. Therefore, it has been approved by the Australian Medicines Agency for use as a disinfectant against SARS-CoV-2, at a concentration of 0.01%15.

The results of an investigation into the use of 0.01% HOCl as an ocular surface antiseptic in intravitreal injection (IVI) prophylaxis showed that the application of 0.01% HOCl spray as a rinse after applying 5% Betadine® provided greater patient comfort10. In addition, the antiseptic coverage provided by the 0.01% HOCl spray was equal to or better than that of Betadine® as it affects most of the pathogens commonly implicated in endophthalmitis. In ophthalmology we have a 0.01% hypochlorous acid eye spray (concentration 100 ppm) marketed as Ocudox® (Ocudox, BrillPharma, Spain) for the treatment of blepharitis due to Meibomian gland dysfunction and for ocular asepsis. It is classified as a medical device and is indicated for the treatment of blepharitis by applying a cotton pad soaked in the product to the base of the eyelashes and upper eyelid. According to its technical data sheet, it does not irritate the eyes, nose or throat, and does not produce cell damage. Neither the duration of its effect nor the maximum dose to be instilled is described, but the product disappears quite quickly (its effect is immediate, in less than 1 min it has the antiseptic action) and the dosage would be similar to that of the hydroalcoholic gels applied for hand disinfection. Hypochlorous acid is also used in dental procedures, in otorhinolaryngology, in the peritoneal cavity, in dermatology and in breast implants, all of them with good tolerance.

Based on the scientific evidence found on the virucidal action of hypochlorous acid at a concentration of 0.01% and despite the fact that its indication as a product for skin disinfection against COVID-19 is not yet registered, the use of the eye spray (0.01%–100 ppm) could be recommended as an additional protection measure for healthcare personnel, for the prevention of infection by SARS-CoV-2, applied directly to the eyes, nose and mouth before putting on the mask and protective goggles, as well as its use after removing the physical protection measures or in the event of possible accidental exposure. Its recommendation could even be considered in the general population to reduce the viral load and/or prevent transmission of the infection.

However, further in vivo clinical studies would be necessary to confirm its effectiveness and safety as a virucidal against SARS-CoV-2, as well as the maximum duration of continuous use.

Go to:

Financing

This research has not received specific support from public sector agencies, the commercial sector or non-profit organisations.

Go to:

Conflict of interest

There is no conflict of interest with the disclosure.

Go to:

Footnotes

☆Please cite this article as: Gessa Sorroche M, Relimpio López I, García-Delpech S, Benítez del Castillo JM. Ácido hipocloroso como antiséptico en la atención al paciente con sospecha de infección por COVID-19. Arch Soc Esp Oftalmol. 2022;97:77–80.

Go to:

References

1. Meyerowitz E.A., Richterman A., Gandhi R.T., Sax P.E. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2020;174:69–79. [PMC free article] [PubMed] [Google Scholar]

2. Li H., Wang Y., Ji M., Pei F., Zhao Q., Zhou Y., et al. Transmission routes analysis of SARS-CoV-2: a systematic review and case report. Front Cell Dev Biol. 2020;8:1–11. [PMC free article] [PubMed] [Google Scholar]

3. Wu P., Duan F., Luo C., Liu Q., Qu X., Liang L., et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138:575–578. [PMC free article] [PubMed] [Google Scholar]

4. Sitaula R.K., Khatri A., Janani M.K., Mandage R., Sadhu S., Madhavan H.N., et al. Unfolding covid-19: lessons-in-learning in ophthalmology. Clin Ophthalmol. 2020;14:2807–2820. [PMC free article] [PubMed] [Google Scholar]

5. Belser J.A., Rota P.A., Tumpey T.M. Ocular tropism of respiratory viruses. Microbiol Mol Biol Rev. 2013;77:144–156. [PMC free article] [PubMed] [Google Scholar]

6. Sarma P., Kaur H., Kaur H., Bhattacharyya J., Prajapat M., Shekhar N., et al. Ocular manifestations and tear or conjunctival swab PCR positivity for 2019-nCoV in patients with COVID-19: a systematic review and meta-analysis. SSRN Electron J. 2020 [Google Scholar]

7. Xia J., Tong J., Liu M., Shen Y., Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92:589–594. [PMC free article] [PubMed] [Google Scholar]

8. Raboud J., Shigayeva A., McGeer A., Bontovics E., Chapman M., Gravel D., et al. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. PLoS One. 2010;5 [PMC free article] [PubMed] [Google Scholar]

9. CDC . American Academy of Ophthalmology; 2020. WHO. Important coronavirus updates for ophthalmologists; p. 2021. Available from: https://www.aao.org/headline/alert-important-coronavirus-context [Accessed 23 Marcg 2020] [Google Scholar]

10. Balasopoulou A., Kokkinos P., Pagoulatos D., Plotas P., Makri O.E., Georgakopoulos C.D., et al. Symposium recent advances and challenges in the management of retinoblastoma globe-saving treatments. BMC Ophthalmol. 2017;17:1. [PMC free article] [PubMed] [Google Scholar]

11. Mcdonnell G., Russell A.D. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999;12:147–179. [PMC free article] [PubMed] [Google Scholar]

12. Block M.S., Rowan B.G. Hypochlorous acid: a review. J Oral Maxillofac Surg. 2020;78:1461–1466. [PMC free article] [PubMed] [Google Scholar]

13. Epstein F.H., Weiss S.J. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365–376. [PubMed] [Google Scholar]

14. Sakarya S., Gunay N., Karakulak M., Ozturk B., Ertugrul B. Hypochlorous acid: an ideal wound care agent with powerful microbicidal, antibiofilm, and wound healing potency. Wounds. 2014;26:342–350. [PubMed] [Google Scholar]

15. Australian Government Department of Health Therapeutic Goods Administration Disinfectants for use against COVID-19 in the ARTG for legal supply in Australia. Ther Goods Adm. 2020:1–32. [Google Scholar]

16. Speir R.W. Effect of several inorganic salts on infectivity of Mengo virus. Proc Soc Exp Biol Med. 1961;106:402–404. [Google Scholar]

17. Kim H.J., Lee J.G., Kang J.W., Cho H.J., Kim H.S., Byeon H.K., et al. Effects of a low concentration hypochlorous acid nasal irrigation solution on bacteria, fungi, and virus. Laryngoscope. 2008;118:1862–1867. [PubMed] [Google Scholar]

18. Ramalingam S., Cai B., Wong J., Twomey M., Chen R., Fu R.M., et al. Antiviral innate immune response in non-myeloid cells is augmented by chloride ions via an increase in intracellular hypochlorous acid levels. Sci Rep. 2018;8:1–11. [PMC free article] [PubMed] [Google Scholar]

19. Landa-Solis C., González-Espinosa D., Guzmán-Soriano B., Snyder M., Reyes-Terán G., Torres K., et al. Microcyn™: a novel super-oxidized water with neutral pH and disinfectant activity. J Hosp Infect. 2005;61:291–299. [PubMed] [Google Scholar]

20. Taharaguchi M., Takimoto K., Zamoto-Niikura A., Yamada Y.K. Effect of weak acid hypochlorous solution on selected viruses and bacteria of laboratory rodents. Exp Anim. 2014;63:141–147. [PMC free article] [PubMed] [Google Scholar]